Skip to main content
vTv Therapeutics Inc. logo

vTv Therapeutics Inc. — Investor Relations & Filings

Ticker · VTVT ISIN · US9183852048 LEI · 549300WQE5EI9R35SE66 US Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2023-12-12 Regulatory Filings
Country US United States of America
Listing US VTVT

About vTv Therapeutics Inc.

https://vtvtherapeutics.com/

vTv Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. The company's primary commitment is to improving the lives of patients with diabetes. Its lead clinical drug candidate is cadisegliatin, a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. In collaboration with development partners, vTv is also pursuing additional indications for its pipeline molecules, including type 2 diabetes and other chronic conditions.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 11, 2023. It reports that the company, vTv Therapeutics Inc., has regained compliance with Nasdaq's minimum bid price requirement and that its stock listing will continue. The document references prior deficiency notices and a reverse stock split but does not contain financial statements or detailed financial analysis. It is a regulatory announcement about compliance status and listing continuation, not a full financial report or earnings release. The document length is 3890 characters, which is relatively short and consistent with a regulatory filing. Therefore, this document fits best under Regulatory Filings (RNS).
2023-12-12 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by vTv Therapeutics Inc. It reports the approval and effectuation of a reverse stock split (1-for-40) of the company's common stock. The filing includes details about the stock split, the effective date, and the impact on shareholders and stock options. There are no financial statements or detailed financial analysis present, nor is this an announcement of earnings or an annual/interim report. The content focuses on a capital structure change (reverse stock split) to regain compliance with Nasdaq listing requirements. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as stock splits or reverse splits. The document length is sufficient and contains substantive information about the capital change, not merely an announcement of a report or a certification. Therefore, the correct classification is CAP with high confidence.
2023-11-20 English
8-K
Share Issue/Capital Change Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 14, 2023. It announces a corporate action: a reverse stock split at a ratio of 1-for-40 for the company's Class A and Class B common stock. The purpose is to regain compliance with the Nasdaq listing minimum price requirement. The document does not contain financial statements or detailed financial analysis but is an announcement of a capital structure change. This fits the definition of a Share Issue/Capital Change (SHA) filing, which covers announcements regarding stock splits and other capital changes. The document length is 6317 characters, which is sufficient for a detailed announcement rather than a brief notice. Therefore, the correct classification is SHA with high confidence.
2023-11-15 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 15, 2023. It specifically mentions that the company posted an updated slide presentation on its website, which is attached as Exhibit 99.1 and is described as an "Investor Presentation." The text clarifies that this presentation is used in meetings with investors and analysts and may be updated over time. The document does not contain detailed financial statements or comprehensive financial analysis but rather serves to disclose the availability of an investor presentation. The document length is 3782 characters, which is relatively short and consistent with an announcement or filing of a presentation rather than a full report. According to the classification rules, a document that primarily announces or attaches an investor presentation should be classified as Investor Presentation (IP).
2023-11-15 English
10-Q
Interim / Quarterly Report Q3 2023
2023-11-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 9, 2023, by vTv Therapeutics Inc. It announces the issuance of a press release reporting financial results for the fiscal quarter ended September 30, 2023. The document itself does not contain detailed financial statements or substantive financial data but references an attached press release (Exhibit 99.1) that announces the financial results. The length of the document is 3731 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document that announces financial results via a press release and does not contain the full financial data should be classified as an Earnings Release (ER).
2023-11-09 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.